A Prospective, Phase I/II Study of Everolimus and Temozolomide in Patients with Advanced Pancreatic Neuroendocrine Tumor

BACKGROUND: Both everolimus and temozolomide are associated with single-agent activity in patients with pancreatic neuroendocrine tumor (NET). We performed a phase I/II study to evaluate the safety and efficacy of temozolomide in combination with everolimus in patients with advanced pancreatic NET....

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Cancer
Hlavní autoři: Chan, Jennifer A., Blaszkowsky, Lawrence, Stuart, Keith, Zhu, Andrew X., Allen, Jill, Wadlow, Raymond, Ryan, David P., Meyerhardt, Jeffrey, Gonzalez, Marielle, Regan, Eileen, Zheng, Hui, Kulke, Matthew H.
Médium: Artigo
Jazyk:Inglês
Vydáno: 2013
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4308727/
https://ncbi.nlm.nih.gov/pubmed/23733618
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.28142
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky